Donate Toggle Menu
immatics’ Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA (via PR Newswire)

TUEBINGEN, Germany, November 8, 2012 /PRNewswire/ — immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its…